Interferon alfa-2b

Overview

Interferon alpha 2b (human leukocyte clone hif-sn 206 protein moiety reduced). A type I interferon consisting of 165 amino acid residues with arginine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent.

Indication

For the treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma.

Associated Conditions

Chronic Hepatitis B Infection
Chronic Hepatitis C Virus (HCV) Infection
Condylomata Acuminata (External)
Follicular Non-Hodgkin's Lymphoma
Hairy Cell Leukemia (HCL)
Kaposi's Sarcoma
Malignant Melanoma

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
First In Human Study of CX-801 in Advanced Solid Tumors	2024/06/17	NCT06462794	Phase 1	Recruiting	CytomX Therapeutics
Evaluate the Efficacy and Safety of Interferon-α Combined With ATO in the Treatment of Arsenic-resistant APL	2024/06/10	NCT06450145	Not Applicable	Recruiting	Zhejiang Provincial People's Hospital
Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma	2019/09/18	NCT04093323	Phase 2	Terminated	Roswell Park Cancer Institute
Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery	2019/04/02	NCT03899987	Phase 2	Recruiting	Roswell Park Cancer Institute
Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery	2015/07/23	NCT02506153	Phase 3	Active, not recruiting	National Cancer Institute (NCI)
Combination Therapy With Interferon Plus Interleukin 2 and Hepatitis B Vaccine in Chronic Hepatitis B Patients	2015/02/10	NCT02360592	Phase 4	Completed	Tongji Hospital
Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas	2014/12/23	NCT02323659	Phase 4	Terminated	Polish Lymphoma Research Group
Topical Interferon Alfa 2b and Mitomycin C in Conjunctival-Corneal Intraepithelial Neoplasia	2014/07/24	NCT02199327	Phase 4	Completed	Coordinación de Investigación en Salud, Mexico
Interferon α for the Therapy of Minimal Residual Disease	2014/07/09	NCT02185261	Not Applicable	UNKNOWN	Peking University People's Hospital
A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors	2014/06/25	NCT02174172	Phase 1	Completed	Hoffmann-La Roche

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Related News

CytomX Doses First Patient in Combination Trial of CX-801 with Keytruda for Metastatic Melanoma

2 months ago

CytomX Therapeutics has dosed the first patient in a Phase 1 trial combining its masked interferon alpha-2b (CX-801) with Merck's Keytruda in patients with metastatic melanoma.

FDA Approves Ferring Pharmaceuticals' New Manufacturing Facility for Bladder Cancer Gene Therapy ADSTILADRIN

3 months ago

The FDA has approved Ferring Pharmaceuticals' new drug product manufacturing hub in Parsippany, NJ, for production of ADSTILADRIN, the first FDA-approved intravesical gene therapy for high-risk BCG-unresponsive bladder cancer.

Nadofaragene Firadenovec Shows 75% Complete Response Rate in Japanese Phase 3 Trial for BCG-Unresponsive Bladder Cancer

3 months ago

Nadofaragene firadenovec demonstrated a 75% complete response rate at 3 months in Japanese patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, according to new Phase 3 trial data.

Cytokinetics and Pyxis Oncology Announce Key Milestones for 2025; CytomX Prioritizes Pipeline

6 months ago

Cytokinetics anticipates a pivotal year in 2025, focusing on the potential FDA approval and commercial launch of aficamten for obstructive hypertrophic cardiomyopathy (HCM) in the U.S.

CytomX Therapeutics Initiates Combination Therapy Arm in Phase 1 Melanoma Trial

7 months ago

CytomX Therapeutics has dosed the first patient in a combination arm studying CX-801 with Keytruda (pembrolizumab) for patients with metastatic melanoma.

Help Us Improve

Your feedback helps us provide better drug information and insights.

AI-Powered Research

Premium Access